CA2000893A1 - Lipoproteine ayant une activite biologique et son application - Google Patents

Lipoproteine ayant une activite biologique et son application

Info

Publication number
CA2000893A1
CA2000893A1 CA2000893A CA2000893A CA2000893A1 CA 2000893 A1 CA2000893 A1 CA 2000893A1 CA 2000893 A CA2000893 A CA 2000893A CA 2000893 A CA2000893 A CA 2000893A CA 2000893 A1 CA2000893 A1 CA 2000893A1
Authority
CA
Canada
Prior art keywords
lipoprotein
pharmaceutical composition
biologically active
patient
active lipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2000893A
Other languages
English (en)
Other versions
CA2000893C (fr
Inventor
Tore Curstedt
Hans Jornvall
Bjorn Lowenadler
Bengt Robertsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20373667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2000893(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2000893A1 publication Critical patent/CA2000893A1/fr
Application granted granted Critical
Publication of CA2000893C publication Critical patent/CA2000893C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002000893A 1988-10-18 1989-10-17 Lipoproteine ayant une activite biologique et son application Expired - Fee Related CA2000893C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8803713-0 1988-10-18
SE19888803713A SE8803713D0 (sv) 1988-10-18 1988-10-18 Biologically active lipoprotein and its use

Publications (2)

Publication Number Publication Date
CA2000893A1 true CA2000893A1 (fr) 1990-04-18
CA2000893C CA2000893C (fr) 2000-08-08

Family

ID=20373667

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002000893A Expired - Fee Related CA2000893C (fr) 1988-10-18 1989-10-17 Lipoproteine ayant une activite biologique et son application

Country Status (8)

Country Link
US (2) US5223481A (fr)
EP (1) EP0368823B2 (fr)
JP (1) JP2963923B2 (fr)
AT (1) ATE84799T1 (fr)
AU (1) AU623180B2 (fr)
CA (1) CA2000893C (fr)
DE (1) DE68904530T3 (fr)
SE (1) SE8803713D0 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002075A1 (fr) * 1987-09-01 1989-03-09 Teijin Limited Procede d'analyse d'une substance active se trouvant a la surface des poumons chez l'homme
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
AU638474B2 (en) * 1989-07-11 1993-07-01 Genentech Inc. Surfactant compositions and methods
CA2063273C (fr) * 1989-07-11 2002-09-24 Bradley J. Benson Surfactants pulmonaires et methodes
DE69125750D1 (de) * 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
US5258496A (en) * 1990-07-10 1993-11-02 Scios Nova Inc. Isolation and purification of lung surfactant protein
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
JP3961029B2 (ja) * 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
DK0733645T3 (da) * 1993-12-08 2003-07-14 Mitsubishi Pharma Corp Syntetisk peptid, lungeoverfladeaktivt stof indeholdende dette og præparat mod respiratory distress syndrome
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
FR2739860B1 (fr) * 1995-10-17 1998-01-02 Coletica Complexes amphiphiles, procede pour leur preparation et compositions en renfermant
ATE301674T1 (de) * 1996-05-15 2005-08-15 Altana Pharma Ag Verfahren zur trennung und bestimmung von hydrophoben proteinen durch dünnschichtchromatographie
US6476191B1 (en) 1999-02-05 2002-11-05 Mixture Sciences, Inc. Volatilizable solid phase supports for compound synthesis
IT1308180B1 (it) * 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
AU2002338882B2 (en) 2001-10-11 2008-04-03 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Novel use of pulmonary surfactant
CA2575513C (fr) 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprenant un tensioactif pulmonaire et un peptide derive de tnf
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
SI1841458T1 (sl) 2005-01-06 2012-04-30 Discovery Lab Inc Zdravljenje s predpisanim odmerjanjem surfaktanta za zdravljenje ali preprečevanje bronhopulmonalne displazije
JP2007309695A (ja) * 2006-05-16 2007-11-29 Univ Of Tokyo 質量分析のための脂質修飾ペプチドの抽出方法
EP2063903A1 (fr) * 2006-09-19 2009-06-03 Discovery Laboratories, Inc. Formulations de surfactant pulmonaire et procédés favorisant l'élimination du mucus
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
AU2008259768B2 (en) * 2007-06-05 2013-08-29 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
WO2010068754A2 (fr) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Procédés et compositions pour la délivrance de médicaments aux poumons
WO2013188016A2 (fr) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234475A (en) * 1975-08-15 1980-11-18 The Gillette Company Reacting protein with organic acid
DE2925942A1 (de) * 1979-06-27 1981-01-22 Bayer Ag Disazokupferkomplex-reaktivfarbstoffe
US4406833A (en) * 1982-06-04 1983-09-27 Fats And Proteins Research Foundation, Inc. Surfactants derived from fatty acid esters and proteinaceous material
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4933280A (en) * 1984-12-11 1990-06-12 California Biotechnology Inc. Recombinant DNA sequence encoding Alveolar Surfactant Protein
US4918161A (en) * 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
US4882422A (en) * 1985-10-24 1989-11-21 Genetics Institute, Inc. Pulmonary surfactant proteins
WO1987006943A1 (fr) * 1986-05-06 1987-11-19 Children's Hospital Medical Center Proteine associee a un agent tensio-actif hydrophobe pulmonaire d'un poids moleculaire de 6000 daltons, et ses multimeres
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
WO1988003170A1 (fr) * 1986-10-24 1988-05-05 Whitsett Jeffrey A Proteines associees a des agents tensioactifs hydrophobes pulmonaires
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
WO1989000167A1 (fr) * 1987-07-01 1989-01-12 Kabigen Ab Proteines, compositions de proteines et leurs utilisations
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US4993280A (en) * 1989-07-17 1991-02-19 Motorola, Inc. Rotational control assembly

Also Published As

Publication number Publication date
DE68904530T3 (de) 1999-07-08
CA2000893C (fr) 2000-08-08
US5223481A (en) 1993-06-29
EP0368823A3 (en) 1990-05-23
US5455227A (en) 1995-10-03
AU623180B2 (en) 1992-05-07
EP0368823B2 (fr) 1998-12-23
ATE84799T1 (de) 1993-02-15
EP0368823B1 (fr) 1993-01-20
EP0368823A2 (fr) 1990-05-16
JPH02145599A (ja) 1990-06-05
DE68904530D1 (de) 1993-03-04
SE8803713D0 (sv) 1988-10-18
AU4299689A (en) 1990-04-26
DE68904530T2 (de) 1993-07-29
JP2963923B2 (ja) 1999-10-18

Similar Documents

Publication Publication Date Title
CA2000893A1 (fr) Lipoproteine ayant une activite biologique et son application
DE69901284T2 (de) Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
KR100381643B1 (ko) 수면 무호흡증을 치료하기 위한 약제학적 조성물
PL306576A1 (en) Skin moistening composition effective in respect to both superficial and deep layer of human skin and application of such composition
RU97102349A (ru) Композиция для получения лекарственного средства (варианты) и способ ее получения
CA2093806A1 (fr) Methode de traitement ou de prevention du diabete de type 1 par l'administration orale d'insuline
CA2275890A1 (fr) Formulations liquides stables d'interferon
CA2285203A1 (fr) Compositions contenant de la capsaicine ou des analogues de capsaicine et un anesthesique local
EP0233901A1 (fr) Procede et composition permettant de regler les niveaux du calcium serique present dans les mammiferes.
EE03222B1 (et) Inhaleeritavad ravimpreparaadid, protsess nende valmistamiseks ja seade nende kasutamiseks
AU562676B2 (en) Surfactants having pulmonary surface activity
EP0335133A3 (fr) Délivrance d'un médicament à l'aide d'un tensioactif pulmonaire pour faciliter l'absorption
GR20010300075T1 (en) Reduction of liposome-induced adverse physiological reactions
EP0177342A3 (fr) Formulations orales de protéines thérapeutiques
AU3904193A (en) Liposome composition
DE69901314T2 (de) Insulin präparationen enthaltend methanol zur pulmonaren verabreichung
EP1952819A3 (fr) Procédé de prévention de la gastrite au moyen d'amyline ou d'agonistes d'amyline
BE894188A (fr) Formulations pharmaceutiques comprenant de l'insuline et de la pro-insuline humaine
EP1264612A1 (fr) Méthode pour l'administration nasale d'un médicament
FR2513126B1 (fr) Formulations pharmaceutiques comprenant de l'insuline humaine et du c-peptide humain
ATE183651T1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
HUP0002533A2 (hu) Asztmaellenes gyógyszerhatóanyagok új kombinációja
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
IL95892A0 (en) Aroyl-ureas,their preparation and pharmaceutical compositions containing them
GB8804188D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed